As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...
(OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced its ...
The treatment, Lecanemab ... Lecanemab is revolutionary for treating Alzheimer's dementia, Jing said, as the drug treats the disease itself rather than the symptoms. "There is still no cure ...